Founded in 2022, Pheon Therapeutics specializes in developing Antibody-Drug Conjugates (ADCs) for challenging-to-treat cancers. Its primary focus is a first-in-class ADC targeting a novel marker overexpressed in various solid tumors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.